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ABSTRACT
Background    Weight loss in patients with cancer is 
caused by cancer cachexia and chemotherapy-induced 
nausea and vomiting (CINV). Recent developments in 
antiemetic drugs have substantially improved CINV, but 
nutritional intervention did not improve body weight. 
This study aimed to investigate the effects of nutrition 
intervention with appropriate antiemetic treatment in 
patients with non-small-cell lung cancer during chemo-
therapy.
Methods    Patients received individualized nutrition 
counseling by a registered dietitian and were provided 
with oral supplements for 90 days. Body weight and oth-
er parameters were measured at baseline and after 90-
day intervention. To evaluate this nutrition intervention, 
patients were also retrospectively set as control, and then 
body weight change was compared with inverse proba-
bility of treatment weights (IPTW) analysis.
Results    Ten patients received individualized nutrition 
counseling and were provided with oral supplements for 
90 days. Of them, 7 patients consumed nutritional sup-
plements, and the mean intake was 130 kcal/day. After 
90-day intervention, the patients did not show significant 
weight and BMI loss during the course of cytotoxic 
chemotherapy. A total of 38 patients were retrospectively 
enrolled as controls. The number of the patients who 
gain the body weight after 90 days in the study cohort 
was significantly larger than that in the retrospective 
controls with the IPTW analysis (Odds Ratio (OR) = 8.4; 
95% Confidence Interval (CI): 1.6-42; P = 0.01). 
Conclusion    Early intensive nutrition intervention with 
appropriate antiemetic treatment prevents weight loss. 
Nutrition interventions might be also beneficial for qual-
ity of life, treatment response and survival.
Key words    nausea; non-small-cell lung cancer; nutri-
tion intervention; vomiting; weight loss
Weight loss is common among patients with advanced 
cancer and contributes to poor treatment response, 
deterioration in quality of life (QOL) and decreased 
survival.1 There are two types of weight loss in patients 
with cancer: cancer cachexia and chemotherapy-induced 
weight loss.
 Cancer cachexia is particularly common in lung, 
gastric, pancreatic and prostate cancers.2 The patho-
physiology of cachexia is multifactorial and is still 
not well-understood. It is proposed to be the result of 
tumor-host interactions.3 The cachexia guideline expert 
group identified cancer cachexia as a continuum of three 
stage of clinical relevance: pre-cachexia, cachexia and 
refractory cachexia.4 Refractory cachexia represents 
a stage where reversal of weight loss seems no longer 
possible. In this stage, the burdens and risks of artificial 
nutritional support likely outweigh expected benefit. 
Early, namely the stage of pre-cachexia intervention is 
essential.4 
 The major causes of chemotherapy-induced weight 
loss are adverse events such as nausea and vomiting. 
Chemotherapy-induced nausea and vomiting (CINV) is 
the most common and intolerable adverse event of cyto-
toxic chemotherapy. It causes reduced oral intake5 and has 
negative impacts on QOL.6, 7 To prevent chemotherapy-
induced weight loss, several nutrition interventions such 
as dietary counseling (DC) and high-energy oral nutri-
tional supplement (ONS) for patients with advanced can-
cer have been undertaken. However, these interventions 
have shown no improvement in nutritional parameters8-11 
owing to poor compliance to the nutritional intervention 
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and poor treatment outcomes of CINV.8 In brief, uncon-
trollable CINV reduced the positive effects of nutritional 
interventions with DC and ONS.
 Fortunately, recent advances in CINV treatment 
for the past 10 years, particularly the development of 
new-generation antiemetic drugs, has considerably im-
proved outcomes. The efficacy of aprepitant for CINV 
was confirmed in clinical trials globally12-14 including 
in Japan.15 It was approved by the United States Food 
and Drug Administration in 2003 and by the Ministry 
of Health, Labor and Welfare in Japan in 2009. Major 
clinical practice guidelines on antiemetics classify 
cisplatin-based chemotherapies as highly emetogenic 
chemotherapies (HEC) and strongly recommend 
aprepitant-containing 3-drug regimens, including a 5-
hydroxytryptamine 3 receptor antagonist (5-HT3RA) 
and dexamethasone.16-19 Since then, acute- and delayed-
phase CINV has been less severe, and the QOL of pa-
tients with cancer has improved.6, 7
 However, weight loss still occurs frequently despite 
antiemetic treatments in patients with lung cancer during 
cytotoxic chemotherapy. Weight loss is generally caused 
by reduced oral intake and is a serious problem among 
patients with cancer.5 Most previous studies on nutri-
tion interventions with DC and/or ONS8-11 have been 
undertaken before new guidelines on antiemetics have 
been established.16–19 This study aimed to investigate 
the effect of early nutrition intervention on body weight 
during the course of chemotherapy with appropriate 
antiemetic treatments in patients with lung cancer. We 
hypothesized that intensive nutrition intervention may 
prevent chemotherapy-induced weight loss based on the 
appropriate antiemetic treatments.
MATERIALS AND METHODS
Patients
This study is registered in the UMIN registry system 
(No. 000030785). Consecutive patients with histolog-
ically proven inoperable or recurrent non-small-cell 
lung cancer between August 2017 and May 2018 in 
Tottori University Hospital, Japan, who were scheduled 
for the first line cytotoxic chemotherapy were eligible 
for inclusion. Patients received individualized nutrition 
counseling by a registered dietitian and were provided 
with ONS for 90 days. The duration was set based on 
standard period of first line chemotherapy. To evaluate 
the nutrition intervention, we also retrospectively 
enrolled patients as control. The following outcome 
parameters were measured at baseline and 90 days after 
commencing chemotherapy. 
 The following outcome parameters were measured 
at baseline and 90 days after commencing chemotherapy 
(Fig. 1).
Retrospective controls
To compare between patients with and without early 
intensive nutrition intervention, we retrospectively 
reviewed the clinical data and body weight of 38 
consecutive patients with inoperable or recurrent non-
small-cell lung cancer who were given cytotoxic che-
motherapy in Tottori University Hospital between April 
2014 and March 2016. These patients were considered 
as the retrospective controls. They all received three 
or more cycles of cytotoxic chemotherapies with new 
recommended antiemetic drugs.
Nutrition intervention
Patients received individualized nutrition interventions 
in the form of intensive nutrition counseling by a reg-
istered dietitian once a month. They were held in the 
interview room for 30 minutes or more. A registered 
dietitian calculated the total amount of calorie intake 
through counseling and questionnaire (described below 
for details) and determined those with insufficient 
nutrient intake. To estimate total energy needs, physical 
activity and disease factors were included. Basal energy 
expenditure (BEE) was estimated using the Harris 
Benedict equation.20 To calculate total energy expendi-
ture (TEE), we multiplied BEE by an activity factor of 1.4 
by an injury factor of 1.2.21 Based on the actual calorie 
intake and requirements, a registered dietitian provided 
individual sample meal plans, recipe suggestions, and 
suggestions to minimize the side effects of the tumor 
pathology and therapy. They were recommended to 
take nutritional supplements to increase calorie intake. 
Attending doctors, dietitians, and nurses comprised 
the nutrition intervention team, and they conducted a 
nutrition meeting once monthly to discuss the patient’s 
nutrition status and other clinical information.
Nutritional supplement
MHN-02(MEIN, Meiji Dairies Corporation, Tokyo, 
Japan) was used as ONS in this study. In general, MHN-
02 is a whey peptide with anti-inflammatory and antioxi-
dant components such as vitamins C and E and enriched 
trace elements (i.e., zinc and selenium).22 Patients were 
allowed to consume as much as they wanted based on 
nutrition counseling, and the daily intakes were recorded 
in a diary.
Data collection
Anthropometric measurements
Body composition was taken by the same two trained 
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investigators throughout the study and analyzed with 
bioelectrical impedance analysis with an InBody720 
(InBody Japan Corp. Tokyo, Japan). This system uses 
an electrical current at different frequencies (5, 50, 250, 
500, and 1000 kHz) to directly measure the amount of 
extracellular and intracellular water in the body. The 
patient stands with the soles in contact with the foot 
electrodes and grabs the hand electrodes. Data output in-
cluded fat mass, skeletal muscle mass of the total body, 
arms and legs, and basal metabolic rate and was calcu-
lated by using the manufacturer’s algorithm. The muscle 
mass was converted into the skeletal muscle mass index 
(SMI) by dividing the weight by the height squared (kg/
m2). 
Handgrip strength
Handgrip strength was measured using a digital grip-
strength meter (TKK5401; Takei Scientific Instruments 
Co, Ltd, Niigata City, Japan). Participants performed 
the tests twice in both hands in a standing position. The 
mean of measurements was used.
Blood examination
For biochemical testing, total protein, albumin, and he-
moglobin were measured as nutrition indices. C-reactive 
protein and pro-inflammatory cytokines (TNF-α, IL-
6, and IL-1β) were measured as inflammatory markers. 
Standard blood laboratory parameters were analyzed 
using fresh samples in accordance with routine protocols 
at the hospital. Serum pro-inflammatory cytokines were 
measured using commercially available enzyme-linked 
immunosorbent assay kits (R&D systems, Inc. 
Minneapolis, MN).
Quality-of-life assessment
QOL was measured using EuroQol-5 Dimensions, 5 
Levels (EQ-5D-5L). We used Japanese interim EQ-5D 
value set estimated with official crosswalk methodology 
as developed by the EuroQol Group, which is a vali-
dated measure of health-related QOL. It comprises a 
five-dimension health status classification system and a 
separate Visual Analogue Scale.23 
Nutritional status
Patients answered a brief-type self-administered diet his-
tory questionnaire (BDHQ) to provide data for nutrition 
intake estimates.24, 25 The BDHQ comprised four pages 
with 75 questions that assessed dietary habits during 
the past 1 month: 55 questions were related to food con-
sumption and 17 were on cooking and dietary behaviors. 
The daily intake estimates for foods, energy, and select-
ed nutrients were calculated using an ad hoc computer 
algorithm developed for the BDHQ, which was based on 
the Standard Tables of Food Composition in Japan.
 90 days	
Dietary counseling 
Measure outcome parameters 
Nutrition intervention 
•  Provide dietary counseling by a registered dietitian 
over 30 minutes once a month 
•  Calculate the total amount of calorie intake 
•  Indicate insufficient nutrient intake, sample meal plans 
and recipe suggestions 
•  Provide oral nutritional supplements (MHN-02) 
Measure outcome parameters 
•  Anthropometric measurement（InBody 720） 
•  Handgrip strength 
•  Blood examination（nutrition indices, 
inflammatory markers) 
•  QOL（EQ-5D-5L, VAS）　 
•  Nutrition status（BDHQ） 
cytotoxic chemotherapy + appropriate antiemetic treatment	
nutrition intervention + ONS (MHN-02）	
Fig. 1. Flow of research process. Patients received nutrition intervention for 90 days during cytotoxic chemotherapy. Body weight and 
other parameters were measured at baseline and after 90-day intervention. BDHQ, brief-type self-administered diet history questionnaire; 
EQ-5D-5L, EuroQol-5 Dimensions, 5Levels; ONS, oral nutritional supplement; QOL, quality of life; VAS, Visual Analogue Scale.
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CINV
Nausea and vomiting that occurred within 14 days after 
commencing chemotherapy were defined as CINV and 
was graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Event (ver-
sion 4.0).
Statistical Analysis
Continuous data were expressed as mean ± standard 
deviation or median and interquartile range. Outcome 
parameters were compared between at baseline and af-
ter 90-day intervention using paired t-test. Multivariate 
logistic regression analysis was used to compare body 
weight and BMI changes between patients and retro-
spective controls. In addition, inverse probability of 
treatment weighting (IPTW)-adjusted analyses were 
performed to account for baseline differences.26 The 
propensity to undergo nutritional intervention in the 
patients versus retrospective controls was estimated 
using a logistic regression model based on age, sex, 
chemotherapy (platinum-based doublet chemotherapy 
or not), body height, and body weight. Propensity scores 
were then used to derive IPTW, with the inverse of the 
propensity score for patients of the study group and the 
inverse of 1 minus the propensity score for patients of 
the retrospective control group. Then, the generalized 
estimating equations were used to compare body weight 
change during 90 days in the two groups.
 Statistical significance was determined as P < 
0.05 with a two-sided test. All statistical analyses were 
performed using GraphPad Prism 6 software (GraphPad 
Software Inc., San Diego, CA) and SPSS Statistics 25 
(IBM Japan Ltd., Tokyo, Japan).
Ethics
This study was reviewed and approved by the Ethics 
Committee of Tottori University (#1704B001) and was 
performed according to the Declaration of Helsinki.27 
All patients provided written informed consent.
RESULTS
A total of 10 consecutive patients were included. They 
were recruited between August 2017 and May 2018 and 
followed up from August 2018 until trial ended. The co-
hort comprised 6 men and 4 women and the median age 
was 68.5 (range, 28–83) years. Table 1 shows the base-
line characteristics of the patients. All patients received 
cytotoxic chemotherapy; eight patients received three 
cycles of chemotherapy, while two patients received only 
two cycles of chemotherapy because of disease progres-
sion. Eight patients received standard platinum-based 
doublet chemotherapies with recommended aprepitant-
containing 3-drug antiemetic regimens, and the two 
patients received non-platinum single-agent chemothera-
pies with recommended 2-drug antiemetic regimens.
 All patients received 90-day nutrition intervention. 
Table 2 summarizes the outcome parameters of the 
patients. The mean body weight, BMI and QOL mildly 
increased; however, the increases were not statistically 
significant. The highest body weight gain was 6.3 kg, 
and the highest body weight loss was 2.0 kg because 
of disease progression. Handgrip strength showed 
significant decrease, while total SMI, arm SMI and leg 
SMI did not increase between baseline and after 90-day 
intervention.
 The pro-inflammatory cytokines TNF-α, IL-6 and 
IL-1β play a central role in the pathogenesis of cancer-
related body weight loss and cachexia.28, 29 Moreover, 
reduction in inflammation prevents body weight loss and 
cachexia.30, 31 In our study, the amounts of inflammatory 
markers such as CRP, TNF-α, IL-6 and IL-1β were 
higher than normal even at baseline, and they did not de-
Table 1. Patient characteristics of the study cohort
Number n = 10
Age (years), median (range) 68.5 (28–83)
Sex, n (%)
Male 6 (60%)
Female 4 (40%)
Smoking status, n (%)
Never 2 (20%)
Former or current 8 (80%)
Body weight (kg) 56.4 ± 7.3
Body height (m) 1.59 ± 0.1
Body mass index (kg/m2) 22.4 ± 3.9
Histological type, n (%)
Adenocarcinoma 7 (70%)
Squamous cell carcinoma 2 (20%)
Adenosquamous carcinoma 1 (10%)
Mutation status, n (%)
EGFR 1 (10%)
EML4-ALK fusion 1 (10%)
ROS1 fusion 1 (10%)
Wild type or unknown 7 (70%)
Clinical stage, n (%)
IIIB or IV 9 (90%)
Recurrence 1 (10%)
Chemotherapy, n (%)
Platinum-based doublet chemotherapy 8 (80%)
Non-platinum chemotherapy 2 (20%)
EGFR, epidermal growth factor receptor; EML4-ALK, echino-
derm microtubule-associated protein-like 4-anaplastic lymphoma 
kinase fusion; n, number of cases (% total cases); ROS1 fusion, 
c-ros oncogene 1 receptor tyrosine kinase fusion. Data are pre-
sented as the mean ± SD.
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crease after the 90-day intervention. The mean dietetic 
consumption of the participants at baseline was approx-
imately 25% lower than the TEE, which was estimated 
using the Harris Benedict equation. TEE is affected by 
an activity factor and an injury factor. In addition, after 
the 90-day intervention, dietetic consumption did not 
show significant decrease although all patients received 
cytotoxic chemotherapies. Seven of the ten participants 
consumed nutritional supplements, and the mean intake 
was approximately 130 kcal/day. Eicosapentaenoic 
acid (EPA) intake significantly increased after the 90-
day intervention. Meanwhile, there were no significant 
changes in statistics and dietetic consumption of total ki-
localories, proteins, and fat after the 90-day intervention 
(Table 2). 
 In general, the body weight of patients with lung 
cancer tend to decrease during cytotoxic chemotherapy. 
In the present study, there were no remarkable decreases 
of body weight (Table 2). As for a comparison between 
patients with and without early intensive nutrition 
intervention, there were no significant characteristic 
differences between the study cohort and the retrospec-
tive controls. Moreover, the frequency of CINV was not 
significantly different between the two groups (Table 3). 
Meanwhile, compared with the retrospective control, the 
number of the patients who gain the body weight after 
90 days in the study cohort was significantly larger than 
that in the retrospective controls with the IPTW analysis 
[Odds Ratio (OR) = 8.4; 95% Confidence Interval (CI): 
1.6-42; P = 0.01] (Table 4). 
DISCUSSION
Chemotherapy-induced weight loss is among the seri-
ous problems in cancer treatment. The present study 
demonstrated that individualized intensive nutrition 
intervention reduced weight loss during the course of 
cytotoxic chemotherapy. Furthermore, the body weight 
change of the study cohort was significantly different 
with that of the retrospective controls on IPTW analysis. 
The patients received adequate antiemetic drugs and 
high-quality nutritional information and education, 
thereby reducing weight loss during cytotoxic chemo-
Table 2. Outcome parameters of the patients at baseline and after 90-day intervention
Anthropometric measurements Baseline After 90-day intervention P value
Body weight (kg) 56.4 ± 7.3 57.4 ± 7.1 Ns
BMI (kg m-2) 22.4 ± 3.9 22.8 ± 4.3 Ns
SMI (kg m-2) 6.4 ± 0.7 6.4 ± 0.6 Ns
Arm SMI (kg m-2) 1.6 ± 0.3 1.6 ± 0.3 Ns
Leg SMI (kg m-2) 4.7 ± 0.5 4.7 ± 0.3 Ns
Handgrip strength (kg) 24.4 ± 6.7 21.7 ± 6.7 0.012
QOL assessment
QOL (EQ-5D-5L), median (range) 0.84 (0.49–1.00) 0.89 (0.45–1.00) Ns
QOL (VAS) (mm) 70.5 ± 22 71.5 ± 23 Ns
Blood examination
CRP (mg dL-1) 1.39 ± 1.8 1.10 ± 1.8 Ns
TNF-α (pg mL-1) 26.3 ± 5.8 53.3 ± 40 Ns
IL-6 (pg mL-1) 12.9 ± 6.7 9.9 ± 6.2 Ns
IL-1β (pg mL-1) 29.9 ± 22 26.7 ± 21 Ns
Dietetic consumption*
Kcal (Kcal/day) 1618 ± 490 1652 ± 490 Ns
Proteins (g/day) 61.8 ± 19 67.7 ± 28 Ns
CHO (g/day) 226 ± 74 224 ± 92 Ns
Fat (g/day) 46.0 ± 74 51.7 ± 24 Ns
n-3 fatty acid (g/day) 2.0 ± 0.9 2.7 ± 1.4 Ns
α-linolenic acid (g/day) 1.3 ± 0.8 1.6 ± 0.8 Ns
EPA (g/day) 0.22 ± 0.13 0.42 ± 0.26 0.038
DHA (g/day) 0.38 ± 0.18 0.56 ± 0.38 Ns
*After 90-day intervention of dietetic consumption includes both food intake and nutritional supplement.
Data are presented as the mean ± SD. Statistical analysis was performed with paired t-test. P < 0.05 was considered statistically signifi-
cant.
BMI, body mass index; CHO, carbohydrates; CRP, c-reactive protein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EQ-5D-
5L, EuroQol5 dimensions 5 levels; IL-1β, interleukin-1β; IL-6, interleukin-6; Kcal, kilocalories; Ns, not significant; QOL, quality of life; 
SMI, skeletal mass index; TNF-α, tumor necrosis factor; VAS, visual analogue scale.
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Table 3. Comparison of baseline characteristics between patients and retrospective controls
Patients   n = 10 Retrospective controls   n = 38 P value
Age 68.5 (28–83) 73 (40–89) Ns†
Sex, n (%)
Male 6 (60%) 30 (79%) Ns‡
Female 4 (40%) 8 (21%)
Smoking status n (%)
Never 2 (20%) 7 (18%) Ns‡
Former or current 8 (80%) 31 (82%)
Histological type n (%)
Adenocarcinoma 7 (70%) 29 (76%) Ns‡
Squamous cell carcinoma 2 (20%) 9 (24%)
Adenosquamous carcinoma 1 (10%) 0
Best response of chemotherapy n (%)
PR or SD 8 (80%) 35 (92%) Ns‡
PD 2 (20%) 3 (8%)
CINV
Nausea*
All grade 8 (80%) 22 (58%) Ns‡
Grade 3/4 1 (10%) 2 (5%)
Vomiting*
All grade 2 (20%) 4 (11%) Ns‡
Grade 3/4 1 (10%) 2 (5%)
TP (g dL-1) 7.18 ± 0.63 7.15 ± 0.59 Ns†
Alb (g dL-1) 3.88 ± 0.41 4.00 ± 0.44 Ns†
WBC (uL-1) 9400 ± 4500 8000 ± 3500 Ns†
Hb (g dL-1) 13.2 ± 1.34 13.0 ± 1.57 Ns†
Plt (×103 uL-1) 304 ± 110 260 ± 63 Ns†
Cr (mg dL-1) 0.63 ± 0.10 0.73 ± 0.19 Ns†
LDH (U L-1) 257 ± 137 226 ± 71.4 Ns†
CRP (mg dL-1) 1.73 ± 1.76 1.15 ± 1.44 Ns†
*Adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (version 4.0).
†Mann-Whitney test; ‡chi-square test.
Alb, albumin; CINV, chemotherapy-induced nausea and vomiting; Cr, creatinine; CRP, c-reactive protein; Hb, hemoglobin; LDH, lactic 
acid dehydrogenase; n, number of cases (% total cases); Ns, not significant; PD, progressive disease; Plt, platelet; PR, partial response; SD, 
stable disease; TP, total protein; WBC, white blood cell.
Table 4. Body weight change in the study patients and retrospective controls
Patients Retrospective controls
Unadjusted analysis* IPTW analysis†
OR 95% CI P value OR 95% CI P value
n 10 38
Body weight change Gain 6 (60%) 8 (21%) 5.6 1.2–25 0.044 8.4 1.6–42 0.01
Loss 4 (40%) 30 (79%)
IPTW analysis for the study patients versus retrospective controls was estimated using a logistic regression model based on age, sex, 
chemotherapy (platinum-based doublet chemotherapy or non-platinum chemotherapy), body height, and body weight.
*chi-square test; †generalized estimating equations.
CI, confidence interval; IPTW, inverse probability of treatment weight; OR, odds ratio. 
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therapy. 
 In previous studies, nutrition interventions such 
as DC and/or ONS yielded no improvement in body 
weight,9–11 but ONS with EPA and DHA-enriched 
supplementation resulted in a significant improvement 
in patients with cancer during chemotherapy.8, 31–33 
Meanwhile, in the current study, nutrition intervention 
without EPA and DHA-enriched supplement caused 
increased body weight in the patients compared with 
the retrospective control. This outcome might be due to 
two reasons. First, the control of CINV has consider-
ably improved in the past 10 years. The availability of 
aprepitant in addition to other antiemetic agents, such as 
5-HT3RA and dexamethasone, has improved treatment 
outcomes of CINV. Currently, 3-drug regimens (aprepi-
tant, 5-HT3RA and dexamethasone) are strongly recom-
mended to prevent CINV during HEC.16-19 Consequently, 
the present study shows that appropriate nutrition 
intervention with antiemetic drugs prevented reduced 
dietary intake and body weight from CINV. Second, 
dietary intake of EPA and DHA among Japanese is 
generally higher than that in other populations. EPA 
and DHA-enriched supplementation8, 31-33 causes weight 
gain as they can downregulate the production of pro-
inflammatory cytokines and mediate the modulation 
of systemic inflammation.34, 35 As such, EPA and DHA 
reduce anorexia, resting energy expenditure, muscle 
degradation and weight loss.36–39 The EPA and DHA 
intake of Japanese is approximately four-fold higher 
compared to that of Americans. Based on the results of 
the 2005 and 2006 NHNS,40 the median EPA and DHA 
intake of Japanese aged 30-49 years is 0.32 g/day in 
men and 0.23 g/day in women, while it is 0.086 g/day in 
men and 0.063 g/day in women among Americans aged 
31-50 years.41 In this study, the consumption of EPA at 
baseline and after 90-day intervention were 0.22 ± 0.13 
g/day and 0.42 ± 0.26 g/day and DHA at baseline and 
after 90-day intervention were 0.38 ± 0.18 g/day and 0.56 
± 0.38 g/day, respectively. The patients took adequate 
amounts of EPA and DHA daily. For patients who take 
enough fish oil like the Japanese, nutrition intervention 
may have strong effect on preventing weight loss even 
without EPA and DHA supplementation.
 Weight loss in cancer patients administered chemo-
therapy consists of chemotherapy-induced weight loss 
and cancer cachexia. These two are interconnected and 
inseparable. The efficacy of nutritional intervention on 
cancer cachexia was not assessed in this study. In a short 
period of 90-day intervention, the patients had increased 
BMI, while they did not gain SMI, and had reduced grip 
strength. Patients with muscle depletion and low muscle 
attenuation have worse prognoses independent of other 
factors.42 The importance of rehabilitation and exer-
cise for cancer patients has been recently recognized. 
Vigorous exercise and physical activity were associated 
with lower risk of colorectal cancer-related overall 
mortality,43 prostate cancer progression,44 and reduced 
symptoms of lung cancer.45 Future research should pay 
attention to not only nutrition intervention but also phys-
ical intervention, such as rehabilitation or exercise.
 In conclusion, early intensive nutritional intervention 
during chemotherapy resulted in maintenance of body 
weight compared with patients who received standard 
care. With the development of antiemetic drugs to pre-
vent CINV, nutrition interventions such as DC and ONS 
might be beneficial not only for body weight but also 
clinically relevant outcomes such as QOL, treatment 
response and survival. 
LIMITATIONS
This study has some limitations. First, although im-
provements in clinically relevant outcomes such as 
treatment response and survival are primary targets for 
nutrition intervention, the effects of these outcomes had 
not been assessed in this study. Second, the number of 
patients was too small, and this study was single arm. 
Larger randomized trials are required in the future.
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